Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
When we run for a bus or reach for our phones, our bodies instantly translate the oxygen we breathe and our energy reserves into coordinated movement. We don’t have to give it a second thought. However, this is different for people with Pulmonary Arterial Hypertension (PAH). It may be hard to believe, but for people living with PAH simple everyday tasks can feel as tough as climbing Mount Everest.
Advances in the diagnosis and management of PAH have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, prompt and accurate diagnosis of PAH as a rare disease remains a challenge. Scientists and innovators today are developing the next generation of diagnostics & treatments for PAH by leveraging technologies such as stem cell therapy, gene therapy, miRNA technology, and more. But how close are we to breakthrough solutions and what are the latest developments in the space?
Join Johnson & Johnson Innovation, JLABS & Actelion Pharmaceuticals Canada Inc., a Janssen pharmaceutical company of Johnson & Johnson, as we bring together innovators advancing PAH therapies and their new approaches to treatments & diagnostics. These scientific experts will share their data and insights to advance our understanding of this space, and the unique challenges they face in PAH.